-
公开(公告)号：US20140045817A1
公开(公告)日：2014-02-13
申请号：US14057882
申请日：2013-10-18
Applicant: Array BioPharma Inc.
Inventor： Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Hicks , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao
IPC: C07D471/04 , C07D451/06
CPC classification number: C07D471/04 , A61K31/437 , C07D451/06 , C07D519/00
Abstract: Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
Abstract translation: 本文提供了一种在哺乳动物中治疗PIM-1和/或PIM-3和/或PIM-3激酶介导的病症的方法，其包括向所述哺乳动物施用治疗有效量的式I化合物：其中 A，B，R1，R1a，R2，R3，R4，R5，R6和R7具有说明书中给出的含义。
-
![4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors](/abs-image/US/2021/06/08/US11028093B2/abs.jpg.150x150.jpg)
公开(公告)号：US11028093B2
公开(公告)日：2021-06-08
申请号：US16890663
申请日：2020-06-02
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
![4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS](/abs-image/US/2017/12/21/US20170362240A1/abs.jpg.150x150.jpg)
公开(公告)号：US20170362240A1
公开(公告)日：2017-12-21
申请号：US15532937
申请日：2015-12-04
Applicant: ARRAY BIOPHARMA INC. , CELGENE CORPORATION
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06
CPC classification number: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
Patent Agency Ranking
![4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS](/abs-image/US/2019/06/13/US20190177328A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190177328A1
公开(公告)日：2019-06-13
申请号：US16212493
申请日：2018-12-06
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: C07D487/04 , A61K45/06 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
![4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors](/abs-image/US/2019/01/29/US10189845B2/abs.jpg.150x150.jpg)
公开(公告)号：US10189845B2
公开(公告)日：2019-01-29
申请号：US15532937
申请日：2015-12-04
Applicant: ARRAY BIOPHARMA INC. , CELGENE CORPORATION
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
公开(公告)号：US08987251B2
公开(公告)日：2015-03-24
申请号：US14057882
申请日：2013-10-18
Applicant: Array BioPharma Inc.
Inventor： Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Hicks , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao
IPC: A61K31/437 , C07D471/04 , C07D451/06 , C07D519/00
CPC classification number: C07D471/04 , A61K31/437 , C07D451/06 , C07D519/00
Abstract: Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
Abstract translation: 本文提供了一种在哺乳动物中治疗PIM-1和/或PIM-3和/或PIM-3激酶介导的病症的方法，其包括向所述哺乳动物施用治疗有效量的式I化合物：其中 A，B，R1，R1a，R2，R3，R4，R5，R6和R7具有说明书中给出的含义。
-
![4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS](/abs-image/US/2020/09/17/US20200291039A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200291039A1
公开(公告)日：2020-09-17
申请号：US16890663
申请日：2020-06-02
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
![4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors](/abs-image/US/2020/08/04/US10730880B2/abs.jpg.150x150.jpg)
公开(公告)号：US10730880B2
公开(公告)日：2020-08-04
申请号：US16212493
申请日：2018-12-06
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.029 seconds)
